Highest-materiality recent filing
Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)
Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.
Q4 net sales $263.6M (+9.8% YoY); GAAP EPS $1.21 vs $1.03; adjusted EPS $1.31 vs $1.13.
Balchem declares $0.96 annual dividend (10.3% increase), authorizes repurchase of up to 4M shares
Dividend of $0.96 per share declared on Dec 9, 2025, payable Jan 20, 2026 to holders of record Dec 23, 2025.
Balchem Q3 2025: record sales $267.6M, adj. EPS $1.35, all segments grow
Record net sales $267.6M (+11.5% YoY); GAAP EPS $1.24 vs $1.03; adjusted EPS $1.35 vs $1.13.
Balchem Q2 2025: record net sales $255.5M, adj. EPS $1.27 beat
Net sales $255.5M, +9.1% YoY; GAAP EPS $1.17 vs $0.98 prior year quarter.
Balchem Q1 net sales $250.5M record; adj. EPS $1.22 vs $1.03 YoY; all segments grow
Net sales of $250.5M, up 4.5% YoY; GAAP EPS $1.13 vs $0.89; adjusted EPS $1.22 vs $1.03.
Balchem Q4 record net sales $240M, adjusted EBITDA $62.8M, EPS $1.03
Q4 net sales record $240.0M (+4.9% YoY); GAAP EPS $1.03 vs $0.82; adjusted EPS $1.13 vs $0.95.
Balchem Q3 net sales up 4.3% to $239.9M; record adjusted EBITDA $64.4M, up 7.6% YoY
GAAP EPS $1.03 versus $0.90 prior year; adjusted EPS record $1.13 versus $1.04.
Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)
GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.
Balchem reports record Q1 net sales of $239.7M, adjusted EBITDA up 8%
Net sales $239.7M (+3.1% YoY), adjusted EBITDA $60.9M (+8.0% YoY), both all-time records.
Balchem Q4 adj. EBITDA up 5.4% to $55.4M; free cash flow $56M, record Human Nutrition sales
Q4 GAAP EPS $0.82 vs $0.66 prior year; adjusted EPS $0.95 vs $0.94.
Balchem Q3 sales down 5.9% to $229.9M, but EPS up to $0.90; record adjusted EBITDA $59.9M
GAAP EPS $0.90 vs $0.78 prior year; adjusted EPS $1.04 vs $1.00.
Balchem Q2 sales $231.3M (-2.3% YoY); adjusted EPS $1.06; record EBITDA
Q2 net sales $231.3M, down 2.3% YoY; GAAP net earnings $30.1M ($0.93 EPS).
Balchem reports record Q1 sales of $232.5M; net earnings down 21.5% to $22.7M
Record Q1 net sales of $232.5M (+1.6% YoY); gross margin $73.2M.
Balchem Q4 net sales up 9.1% to $232.5M; adjusted EPS $0.94; dividend raised 10.9%
Q4 net sales $232.5M (+9.1% YoY); GAAP net earnings $21.4M (-14.2%); adjusted net earnings $30.3M (+9.1%).
Balchem declares Q4 dividend $0.71/share, 10.9% increase; 14th consecutive annual raise
Dividend of $0.71 per share payable Jan 20, 2023 to holders of record Dec 27, 2022.
Balchem Q3 revenue up 23.4% to $244.3M; adjusted EPS $1.00 vs $0.92 YoY
Net sales $244.3M (+23.4% YoY); GAAP EPS $0.78, adjusted EPS $1.00.
Balchem grants CEO Harris 130,000 options; $6.3M value for retention
130,000 stock options awarded to CEO Ted Harris with grant date Sep 15, 2022; fair value ~$6.3M.
Balchem Q2 record net sales $236.7M (+17% YoY), GAAP EPS $0.92, adj. EPS $1.07
Record net sales $236.7M, up 17% YoY; GAAP EPS $0.92, adjusted EPS $1.07 (record).
Balchem closes $332.5M acquisition of Kappa Bioscience, financed via credit facility and cash
Purchase price ~NOK 3.3B ($332.5M) includes assumption and repayment of NOK 303.5M ($30.6M) of Kappa debt.
Balchem to acquire Kappa Bioscience for $338M; accretive to EPS in 2022
Enterprise value of NOK 3.175B (~$338M); EV/EBITDA multiple of 18x on 2022 forecast.
Net sales $228.9M (+23.3% YoY); GAAP net earnings $28.9M (+23.6% YoY); diluted GAAP EPS $0.89.
Balchem Q4 record sales $213M (+17.9% YoY); adj. EPS $0.85; dividend up 10.3%
Q4 net sales $213.1M (+17.9% YoY); GAAP EPS $0.76, adjusted EPS $0.85 (up from $0.83).
Balchem reports record Q3 2021 sales of $197.9M, net earnings $25.0M, EPS $0.77
Net sales $197.9M, up 13% YoY; record sales in all three segments: Human Nutrition, Animal Nutrition, and Specialty Products.
Balchem reports record Q2 sales of $202.4M, GAAP EPS $0.70, adjusted EPS $0.93, up 16.7% YoY
Record Q2 net sales $202.4M, up 16.7% YoY; all three segments set records.
William A. Backus, Vice President and Chief Accounting Officer, has notified the Company of his intent to retire from his position on March 31, 2026.
On October 16, 2024, the Corporate Governance and Nominating Committee of the Balchem Corporation (“Balchem”) Board of Directors (the “Board”) accepted the resignation of Joyce Lee as a Director.
On March 27, 2024, Balchem Corporation (the “Company”) announced that Jonathan H. Griffin, Senior Vice President and General Manager, Animal Nutrition and Health, would be moving into the role of Senior Vice President, Corporate Development, effective immediately.
On September 1, 2023, the Board of Directors (the “Board”) of Balchem Corporation (the “Company”) elected Olivier Rigaud and Monica Vicente to the Board, effective as of September 6, 2023, respectively.
On September 1, 2023, the Board of Directors (the “Board”) of Balchem Corporation (the “Company”) elected Olivier Rigaud and Monica Vicente to the Board, effective as of September 6, 2023, respectively.
James C. Hyde, Senior Vice President and General Manager, Human Nutrition & Health, has notified the Company of his intent to retire from his role and that he will step down upon the appointment of his successor.
On June 7, 2022, Balchem Corporation (the “ Company ”) announced that Mark Stach, General Counsel and Secretary of the Company, has notified the Company of his intent to retire and will step down upon the appointment of his successor.
Max materiality 0.80 · Median 0.60 · Most common event earnings